Testosterone Undecanoate Injection (Aveed)

Aetna covers Aveed (testosterone undecanoate) for primary hypogonadism or hypogonadotropic hypogonadism in biological males or those identifying as male age ≥18 with ≥2 confirmed low morning total testosterone levels, and for gender‑affirming therapy in adults (and adolescents at Tanner stage ≥2) with documented gender dysphoria; it excludes age‑related (late‑onset) hypogonadism, female sexual dysfunction, heart failure, cognitive enhancement in aging men, most males <18 (except the specified adolescent gender‑dysphoria criteria), menopause, and ALS. Key requirements: precertification is required, use of Aveed is limited to members who have contraindication/intolerance or inadequate response to Depo‑Testosterone (testosterone cypionate) (brand‑selection), patients must be informed of risks/contraindications and fertility preservation, and reauthorization requires the same prior diagnostic/lab confirmation and clinical oversight.

"For gender dysphoria treatment in members under 18 years of age, medication must be prescribed by or in consultation with a provider specialized in the care of transgender youth (e."